Differential effects of oral doxercalciferol (Hectorol®) or paricalcitol (Zemplar®) in the cyp27b1-null mouse model of uremia

Nephron - Experimental Nephrology

Volumn 119, Issue 3, 2011, Pages

  St Arnaud, René ^a,b   Arabian, Alice ^a   Akhouayri, Omar ^a   Knutson, Joyce C ^c   Strugnell, Stephen A ^c  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Genzyme Corporation   (United States)

Author keywords

25 hydroxyvitamin D 1 hydroxylase; Bone; Doxercalciferol; Parathyroid hormone; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CREATININE; DOXERCALCIFEROL; DRUG VEHICLE; NITROGEN; PARATHYROID HORMONE; PARICALCITOL; 1 ALPHA-HYDROXYERGOCALCIFEROL; ERGOCALCIFEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; DRUG EFFECT; HYPOCALCEMIA; KIDNEY FAILURE; MOUSE; NEPHRECTOMY; NONHUMAN; OSTEITIS FIBROSA; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; UREA NITROGEN BLOOD LEVEL; UREMIA; ANIMAL; BLOOD; DEFICIENCY; DOSE RESPONSE; GENETICS; KNOCKOUT MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; OSTEITIS; PATHOLOGY;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADMINISTRATION, ORAL; ANIMALS; CALCITRIOL; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; MICE; MICE, KNOCKOUT; OSTEITIS; OSTEOMALACIA; PARATHYROID HORMONE; UREMIA;

EID: 80051636607     PISSN: 16602129     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000329663     Document Type: Article

References (33)

1. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002; 17: 2094-2105. (Pubitemid 35416745)
2. Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997; 29: 496-502. (Pubitemid 27155269)
3. Salusky IB: Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol 2005; 20: 393-398. (Pubitemid 40309950)
4. Llach F, Fernandez E: Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int Suppl 2003;S113-S119. (Pubitemid 37321351)
5. Slatopolsky E, Gonzalez E, Martin K: Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003; 21: 318-326. (Pubitemid 37116962)
6. Steddon SJ, Fan SL, Cunningham J: New prospects for the management of renal bone disease. Nephron Clin Pract 2005; 99:c1-c7.
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483. (Pubitemid 30318271)
8. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701. (Pubitemid 34158168)
9. Raggi P, Kleerekoper M: Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 836-843.
10. Sjoden G, Smith C, Lindgren U, DeLuca HF: 1 alpha-hydroxyvitamin D 2 is less toxic than 1 alpha-hydroxyvitamin D 3 in the rat. Proc Soc Exp Biol Med 1985; 178: 432-436. (Pubitemid 15141368)
11. Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H: A new analog of calcitriol, 19-Nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860.
12. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-S201.
13. Drueke TB: Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens 2005; 14: 343-349. (Pubitemid 40863071)
14. Frazao JM, Chesney RW, Coburn JW: Intermittent oral 1alpha-hydroxyvitamin D 2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol Dial Transplant 1998; 13(suppl 3):68-72. (Pubitemid 28154348)
15. Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36: 550-561.
16. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432. (Pubitemid 28354552)
17. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532-543. (Pubitemid 32195292)
18. Knutson JC, LeVan LW, Valliere CR, Bishop CW: Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D 2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D 2 , calcitriol, and calcipotriol. Biochem Pharmacol 1997; 53: 829-837. (Pubitemid 27147916)
19. St-Arnaud R, Arabian A, Yu VW, Akhouayri O, Knutson JC, Strugnell SA: 1alpha,24(S) (OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism. J Endocrinol Invest 2008; 31: 711-717.
20. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004; 15: 2219-2228. (Pubitemid 39031361)
21. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E: A new analog of 1,25-(OH)2D3, 19-Nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-112. (Pubitemid 27284381)
22. Dardenne O, Prud'homme J, Arabian A, Glorieux FH, St-Arnaud R: Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin Ddeficiency rickets. Endocrinology 2001; 142: 3135-3141. (Pubitemid 32575552)
23. Dardenne O, Prud'homme J, Hacking SA, Glorieux FH, St-Arnaud R: Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003; 32: 332-340. (Pubitemid 36410315)
24. Dickson GR: Methods of calcified tissue preparation. New York, Elsevier, 1984.
25. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 1987; 2: 595-610.
26. Hernandez JD, Wesseling K, Salusky IB: Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial 2005; 18: 290-295. (Pubitemid 41159578)
27. Lotinun S, Sibonga JD, Turner RT: Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology 2005; 146: 4074-4081. (Pubitemid 41175779)
28. Dardenne O, Prudhomme J, Hacking SA, Glorieux FH, St-Arnaud R: Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D 3 : biochemical, histomorphometric, and biomechanical analyses. J Bone Miner Res 2003; 18: 637-643. (Pubitemid 36899313)
29. Martin KJ, Gonzalez EA: Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001; 38: 1430-1436. (Pubitemid 34193138)
30. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993; 43: 436-442. (Pubitemid 23162839)
31. Malluche HH, Monier-Faugere MC: Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol 2000; 54: 309-317.
32. Westenfeld R, Schafer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W: Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007; 22: 1537-1546. (Pubitemid 47073751)
33. Richard-Fiardo P, Payen E, Chevre R, Zuber J, Letrou-Bonneval E, Beuzard Y, Pitard B: Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Hum Gene Ther 2008; 19: 331-342. (Pubitemid 351591425)